{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:26:28Z","timestamp":1783193188629,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.urology.2024.06.020","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T06:45:22Z","timestamp":1718779522000},"page":"61-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Sequential Intravesical Chemotherapy for Treatment Na\u00efve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls"],"prefix":"10.1016","volume":"192","author":[{"given":"Justin M.","family":"Refugia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Roebuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenzie","family":"Needham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Hemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matvey","family":"Tsivian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2024.06.020_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2024.06.020_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2024.06.020_bib3","first-page":"156","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci"},{"key":"10.1016\/j.urology.2024.06.020_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12957-018-1497-0","article-title":"Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies","volume":"16","author":"Shen","year":"2018","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.urology.2024.06.020_bib5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib6","first-page":"227","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder\u00a0cancer"},{"key":"10.1016\/j.urology.2024.06.020_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.urology.2018.07.055","article-title":"Utilization of Bacillus Calmette-Guerin for nonmuscle invasive bladder cancer in an era of Bacillus Calmette-Guerin supply shortages","volume":"124","author":"Khanna","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.06.020_bib8","unstructured":"BCG Shortage Info: American Urological Association; 2020 [Available from: \u3008https:\/\/www.auanet.org\/about-us\/bcg-shortage-info\u3009."},{"key":"10.1016\/j.urology.2024.06.020_bib9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib10","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.euf.2021.07.018","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer: pro","volume":"8","author":"Roumiguie","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2024.06.020_bib11","first-page":"901","article-title":"Early experience with intravesical gemcitabine-docetaxel for BCG-na\u00efve patients with high grade non-muscle invasive bladder cancer","volume":"38","author":"Babajide","year":"2020","journal-title":"Urol\u00a0Oncol\u00a0Semin\u00a0Ori\u00a0Investig"},{"key":"10.1016\/j.urology.2024.06.020_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.urology.2024.06.020_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urology.2024.06.020_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urology.2024.06.020_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","article-title":"Bacillus Calmette-Guerin (BCG) vaccine:\u00a0a\u00a0global assessment of demand and supply balance","volume":"36","author":"Cernuschi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.urology.2024.06.020_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urology.2024.06.020_bib20","doi-asserted-by":"crossref","unstructured":"McElree I.M., Mott S.L., O'Donnell M.A., Packiam V.T. Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer. BJU Int. 2023;133: 671-673. Doi: https:\/\/doi.org\/10.1111\/bju.16208.","DOI":"10.1111\/bju.16208"},{"key":"10.1016\/j.urology.2024.06.020_bib21","first-page":"589","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus calmette-Gu\u00e9rin-Na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib22","article-title":"Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions","volume":"926","author":"Li","year":"2022","journal-title":"Eur\u00a0J\u00a0Pharmacol"},{"key":"10.1016\/j.urology.2024.06.020_bib23","unstructured":"ASCO Daily News. An update on the supply and production of bacille Calmette-Gu\u00e9rin. https:\/\/dailynews.ascopubs.org\/do\/update-supply-and-production-bacille-calmette-guerin. 2023."},{"key":"10.1016\/j.urology.2024.06.020_bib24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000002779","article-title":"Sequential chemotherapy with gemcitabine and docetaxel: breaking the chains of bacillus Calmette-Guerin","volume":"208","author":"Meeks","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.06.020_bib25","unstructured":"Group E-ACR, Institute NC, Group ECO. Intravesical BCG vs GEMDOCE in NMIBC. \u3008https:\/\/classic.clinicaltrials.gov\/show\/NCT05538663\u3009; 2023."},{"key":"10.1016\/j.urology.2024.06.020_bib26","first-page":"S1224","article-title":"2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.urology.2024.06.020_bib27","unstructured":"CG ONCOLOGY I. Cretostimogene Grenadenorepvec Clinical Studies. 2023. Available from: \u3008https:\/\/cgoncology.com\/pipeline\/\u3009."}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524004631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524004631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T18:56:01Z","timestamp":1727463361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524004631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":27,"alternative-id":["S0090429524004631"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2024.06.020","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Intravesical Chemotherapy for Treatment Na\u00efve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2024.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}